Medscape17h
Dry Age-Related Macular Degeneration Highlights From ASRS 2024
Dr Khanani begins with the GALE study, which demonstrated that pegcetacoplan (PEG) provided benefit in visual function on a ...
Medscape15d
Novel Drug Targeting C3/C3b Shows Benefits in Rare C3 Glomerulopathy and Primary IC-MPGN
Pegcetacoplan substantially reduced proteinuria in these potentially debilitating rare kidney diseases in a new phase 3 study ...
Yahoo Finance18d
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
The results highlighted the strength of systemic pegcetacoplan treatment in patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN ...
Yahoo Finance17d
Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment effect in patients with C3G / primary IC-MPGN
The results highlighted the potential of systemic pegcetacoplan treatment in patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which ...
Morningstar17d
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
Statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4 All secondary endpoints favored treatment with pegcetacoplan ...
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...